Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Gastrointestinal manifestations in primary immunodeficiency

Asghar Aghamohammadi, MD, PhD
Atefeh Zeinoddini, MD
Payam Mohammadinejad, MD
Nima Rezaei, MD, PhD
Section Editor
Luigi D Notarangelo, MD
Deputy Editor
Anna M Feldweg, MD


Gastrointestinal (GI) manifestations are the second most common complications of primary immunodeficiency (PID) after pulmonary disease and have been reported in approximately 5 to 50 percent of patients with different types of PID [1,2]. PID may initially present with GI manifestations, such as intractable diarrhea, malabsorption, failure to thrive (FTT), or inflammatory bowel disease, which often do not respond as expected to conventional therapies [3].

This topic review will provide a brief overview of the GI immune system, review the most common GI complications of PID, and discuss specific GI disorders in some of the more common PIDs. Initial testing for immune problems, monitoring for GI complications among PID patients, and treatment considerations are also reviewed. More detailed approaches to patients with suspected PID and the medical management of immunodeficiency are discussed separately. (See "Approach to the child with recurrent infections" and "Approach to the adult with recurrent infections" and "Laboratory evaluation of the immune system" and "Primary immunodeficiency: Overview of management".)


The gastrointestinal (GI) tract is considered the largest organ in the immune system, with a vast surface area and the largest reservoir of lymphocytes in the human body [4]. The GI immune system consists of physical barriers, gut-associated lymphoid tissue (GALT), and other lymphoid organs. Components of the GI immune system are discussed in more detail separately. (See "Pathogenesis of food allergy", section on 'The gut immune system'.)

The GI immune system is constantly exposed to a variety of foreign antigens including those from bacteria, viruses, and parasites, as well as foreign dietary proteins [5]. A balance between immune responses to harmful micro-organisms and tolerance to nonpathogenic antigens is essential for immune homeostasis in the GI tract, a process that generally favors the development of tolerance. The GI immune system is mainly regulated by T lymphocytes, specifically regulatory T (Treg) cells, which are also responsible for cellular immunity and initiation of antigen-specific immune responses [6,7].

In addition, dimeric secretory immunoglobulin A (IgA), which is synthesized and secreted in the GI tract (and thus distinct from monomeric serum IgA), plays an active role in the regulation of the GI immune system by inducing tolerance to antigens with insignificant pathogenesis as well as providing protection against invasive micro-organisms. It is possible that dysregulation of IgA could result in inflammatory processes in the GI tract [8]. In addition, defects in either humoral or cellular immunity could result in uncontrolled inflammatory processes, damage to the mucosal surface of the GI tract, and increased risk of developing chronic inflammatory, autoimmune, and even malignant disorders.

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Jan 26, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Lai Ping So A, Mayer L. Gastrointestinal manifestations of primary immunodeficiency disorders. Semin Gastrointest Dis 1997; 8:22.
  2. Wood P, Stanworth S, Burton J, et al. Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review. Clin Exp Immunol 2007; 149:410.
  3. Agarwal S, Mayer L. Diagnosis and treatment of gastrointestinal disorders in patients with primary immunodeficiency. Clin Gastroenterol Hepatol 2013; 11:1050.
  4. McCabe RP. Gastrointestinal Manifestations of Non-AIDS Immunodeficiency. Curr Treat Options Gastroenterol 2002; 5:17.
  5. Kalha I, Sellin JH. Common variable immunodeficiency and the gastrointestinal tract. Curr Gastroenterol Rep 2004; 6:377.
  6. Raghavan S, Quiding-Järbrink M. Regulatory T cells in gastrointestinal tumors. Expert Rev Gastroenterol Hepatol 2011; 5:489.
  7. Barnes MJ, Powrie F. Regulatory T cells reinforce intestinal homeostasis. Immunity 2009; 31:401.
  8. Cerutti A, Rescigno M. The biology of intestinal immunoglobulin A responses. Immunity 2008; 28:740.
  9. Russell GR, Bousvaros A, Walker WA. Gastroenterologic and liver disorders. In: Immunologic disorders in infants and children, 5th ed, Stiehm ER, Ochs HD, Winkelstein JA (Eds), Elsevier, Philadelphia 2004. p.1055.
  10. Kobrynski LJ, Mayer L. Diagnosis and treatment of primary immunodeficiency disease in patients with gastrointestinal symptoms. Clin Immunol 2011; 139:238.
  11. Kadaoui KA, Corthésy B. Secretory IgA mediates bacterial translocation to dendritic cells in mouse Peyer's patches with restriction to mucosal compartment. J Immunol 2007; 179:7751.
  12. Phalipon A, Cardona A, Kraehenbuhl JP, et al. Secretory component: a new role in secretory IgA-mediated immune exclusion in vivo. Immunity 2002; 17:107.
  13. Monteiro RC. Role of IgA and IgA fc receptors in inflammation. J Clin Immunol 2010; 30:1.
  14. Al-Muhsen SZ. Gastrointestinal and hepatic manifestations of primary immune deficiency diseases. Saudi J Gastroenterol 2010; 16:66.
  15. Kumar V, Jarzabek-Chorzelska M, Sulej J, et al. Celiac disease and immunoglobulin a deficiency: how effective are the serological methods of diagnosis? Clin Diagn Lab Immunol 2002; 9:1295.
  16. Prince HE, Norman GL, Binder WL. Immunoglobulin A (IgA) deficiency and alternative celiac disease-associated antibodies in sera submitted to a reference laboratory for endomysial IgA testing. Clin Diagn Lab Immunol 2000; 7:192.
  17. Arkwright PD, Abinun M, Cant AJ. Autoimmunity in human primary immunodeficiency diseases. Blood 2002; 99:2694.
  18. Wang N, Shen N, Vyse TJ, et al. Selective IgA deficiency in autoimmune diseases. Mol Med 2011; 17:1383.
  19. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004; 126:1504.
  20. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448:427.
  21. Rambaud JC, De Saint-Louvent P, Marti R, et al. Diffuse follicular lymphoid hyperplasia of the small intestine without primary immunoglobulin deficiency. Am J Med 1982; 73:125.
  22. Matuchansky C, Morichau-Beauchant M, Touchard G, et al. Nodular lymphoid hyperplasia of the small bowel associated with primary jejunal malignant lymphoma. Evidence favoring a cytogenetic relationship. Gastroenterology 1980; 78:1587.
  23. Matuchansky C, Touchard G, Lemaire M, et al. Malignant lymphoma of the small bowel associated with diffuse nodular lymphoid hyperplasia. N Engl J Med 1985; 313:166.
  24. Kahn LB, Novis BH. Nodular lymphoid hyperplasia of the small bowel associated with primary small bowel reticulum cell lymphoma. Cancer 1974; 33:837.
  25. Castellano G, Moreno D, Galvao O, et al. Malignant lymphoma of jejunum with common variable hypogammaglobulinemia and diffuse nodular hyperplasia of the small intestine. A case study and literature review. J Clin Gastroenterol 1992; 15:128.
  26. Aghamohammadi A, Cheraghi T, Gharagozlou M, et al. IgA deficiency: correlation between clinical and immunological phenotypes. J Clin Immunol 2009; 29:130.
  27. Tuano KS, Orange JS, Sullivan K, et al. Food allergy in patients with primary immunodeficiency diseases: prevalence within the US Immunodeficiency Network (USIDNET). J Allergy Clin Immunol 2015; 135:273.
  28. Twomey JJ, Jordan PH Jr, Laughter AH, et al. The gastric disorder in immunoglobulin-deficient patients. Ann Intern Med 1970; 72:499.
  29. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 1999; 92:34.
  30. Chapel H, Cunningham-Rundles C. Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol 2009; 145:709.
  31. Daniels JA, Lederman HM, Maitra A, Montgomery EA. Gastrointestinal tract pathology in patients with common variable immunodeficiency (CVID): a clinicopathologic study and review. Am J Surg Pathol 2007; 31:1800.
  32. Oksenhendler E, Gérard L, Fieschi C, et al. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis 2008; 46:1547.
  33. Dhalla F, da Silva SP, Lucas M, et al. Review of gastric cancer risk factors in patients with common variable immunodeficiency disorders, resulting in a proposal for a surveillance programme. Clin Exp Immunol 2011; 165:1.
  34. Banka S, Ryan K, Thomson W, Newman WG. Pernicious anemia - genetic insights. Autoimmun Rev 2011; 10:455.
  35. Chapel H, Lucas M, Lee M, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 2008; 112:277.
  36. Khodadad A, Aghamohammadi A, Parvaneh N, et al. Gastrointestinal manifestations in patients with common variable immunodeficiency. Dig Dis Sci 2007; 52:2977.
  37. Yel L. Selective IgA deficiency. J Clin Immunol 2010; 30:10.
  38. Istrate C, Hinkula J, Hammarström L, Svensson L. Individuals with selective IgA deficiency resolve rotavirus disease and develop higher antibody titers (IgG, IgG1) than IgA competent individuals. J Med Virol 2008; 80:531.
  39. Brandtzaeg P, Bjerke K, Kett K, et al. Production and secretion of immunoglobulins in the gastrointestinal tract. Ann Allergy 1987; 59:21.
  40. Meini A, Pillan NM, Villanacci V, et al. Prevalence and diagnosis of celiac disease in IgA-deficient children. Ann Allergy Asthma Immunol 1996; 77:333.
  41. Chow MA, Lebwohl B, Reilly NR, Green PH. Immunoglobulin A deficiency in celiac disease. J Clin Gastroenterol 2012; 46:850.
  42. Piaścik M, Rydzewska G, Pawlik M, et al. Diffuse nodular lymphoid hyperplasia of the gastrointestinal tract in patient with selective immunoglobulin A deficiency and sarcoid-like syndrome--case report. Adv Med Sci 2007; 52:296.
  43. Mir-Madjlessi SH, Vafai M, Khademi J, Kamalian N. Coexisting primary malignant lymphoma and adenocarcinoma of the large intestine in an IgA-deficient boy. Dis Colon Rectum 1984; 27:822.
  44. Cellier C, Foray S, Hermine O. Regional enteritis associated with enterovirus in a patient with X-linked agammaglobulinemia. N Engl J Med 2000; 342:1611.
  45. Misbah SA, Spickett GP, Ryba PC, et al. Chronic enteroviral meningoencephalitis in agammaglobulinemia: case report and literature review. J Clin Immunol 1992; 12:266.
  46. Quartier P, Foray S, Casanova JL, et al. Enteroviral meningoencephalitis in X-linked agammaglobulinemia: intensive immunoglobulin therapy and sequential viral detection in cerebrospinal fluid by polymerase chain reaction. Pediatr Infect Dis J 2000; 19:1106.
  47. Lavilla P, Gil A, Rodríguez MC, et al. X-linked agammaglobulinemia and gastric adenocarcinoma. Cancer 1993; 72:1528.
  48. Bachmeyer C, Monge M, Cazier A, et al. Gastric adenocarcinoma in a patient with X-linked agammaglobulinaemia. Eur J Gastroenterol Hepatol 2000; 12:1033.
  49. van der Meer JW, Weening RS, Schellekens PT, et al. Colorectal cancer in patients with X-linked agammaglobulinaemia. Lancet 1993; 341:1439.
  50. Brosens LA, Tytgat KM, Morsink FH, et al. Multiple colorectal neoplasms in X-linked agammaglobulinemia. Clin Gastroenterol Hepatol 2008; 6:115.
  51. Durandy A, Peron S, Fischer A. Hyper-IgM syndromes. Curr Opin Rheumatol 2006; 18:369.
  52. Winkelstein JA, Marino MC, Ochs H, et al. The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine (Baltimore) 2003; 82:373.
  53. Kerkar N, Miloh T. Sclerosing cholangitis: pediatric perspective. Curr Gastroenterol Rep 2010; 12:195.
  54. Stephan JL, Vlekova V, Le Deist F, et al. Severe combined immunodeficiency: a retrospective single-center study of clinical presentation and outcome in 117 patients. J Pediatr 1993; 123:564.
  55. Bakare N, Menschik D, Tiernan R, et al. Severe combined immunodeficiency (SCID) and rotavirus vaccination: reports to the Vaccine Adverse Events Reporting System (VAERS). Vaccine 2010; 28:6609.
  56. Hoffmann-Fezer G, Gall C, Zengerle U, et al. Immunohistology and immunocytology of human T-cell chimerism and graft-versus-host disease in SCID mice. Blood 1993; 81:3440.
  57. Lefton-Greif MA, Crawford TO, McGrath-Morrow S, et al. Safety and caregiver satisfaction with gastrostomy in patients with Ataxia Telangiectasia. Orphanet J Rare Dis 2011; 6:23.
  58. Buckley RH. Primary immunodeficiency diseases due to defects in lymphocytes. N Engl J Med 2000; 343:1313.
  59. Spacey SD, Gatti RA, Bebb G. The molecular basis and clinical management of ataxia telangiectasia. Can J Neurol Sci 2000; 27:184.
  60. Thrasher AJ, Burns SO. WASP: a key immunological multitasker. Nat Rev Immunol 2010; 10:182.
  61. Cannioto Z, Berti I, Martelossi S, et al. IBD and IBD mimicking enterocolitis in children younger than 2 years of age. Eur J Pediatr 2009; 168:149.
  62. Dupuis-Girod S, Medioni J, Haddad E, et al. Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics 2003; 111:e622.
  63. Minegishi Y. Hyper-IgE syndrome. Curr Opin Immunol 2009; 21:487.
  64. Stover DG, Freeman AF, Wright PW, et al. Diverticulitis in a young man with hyper-IgE syndrome. South Med J 2010; 103:1261.
  65. Alberti-Flor JJ, Granda A. Ileocecal histoplasmosis mimicking Crohn's disease in a patient with Job's syndrome. Digestion 1986; 33:176.
  66. Hutto JO, Bryan CS, Greene FL, et al. Cryptococcosis of the colon resembling Crohn's disease in a patient with the hyperimmunoglobulinemia E-recurrent infection (Job's) syndrome. Gastroenterology 1988; 94:808.
  67. Steiner SJ, Kleiman MB, Corkins MR, et al. Ileocecal histoplasmosis simulating Crohn disease in a patient with hyperimmunoglobulin E syndrome. Pediatr Infect Dis J 2009; 28:744.
  68. Hwang EH, Oh JT, Han SJ, Kim H. Colon perforation in hyperimmunoglobulin E syndrome. J Pediatr Surg 1998; 33:1420.
  69. Su HC, Jing H, Zhang Q. DOCK8 deficiency. Ann N Y Acad Sci 2011; 1246:26.
  70. Savova R, Arshinkova M, Houghton J, et al. Clinical Case of Immune Dysregulation, Polyendocrinopaty, Enteropathy, X-Linked (IPEX) Syndrome with Severe Immune Deficiency and Late Onset of Endocrinopathy and Enteropathy. Case Rep Med 2014; 2014:564926.
  71. Torgerson TR. Immune dysregulation in primary immunodeficiency disorders. Immunol Allergy Clin North Am 2008; 28:315.
  72. Patey-Mariaud de Serre N, Canioni D, Ganousse S, et al. Digestive histopathological presentation of IPEX syndrome. Mod Pathol 2009; 22:95.
  73. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19:683.
  74. Kotlarz D, Beier R, Murugan D, et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology 2012; 143:347.
  75. Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009; 361:2033.
  76. Latour S, Aguilar C. XIAP deficiency syndrome in humans. Semin Cell Dev Biol 2015; 39:115.
  77. Speckmann C, Lehmberg K, Albert MH, et al. X-linked inhibitor of apoptosis (XIAP) deficiency: the spectrum of presenting manifestations beyond hemophagocytic lymphohistiocytosis. Clin Immunol 2013; 149:133.
  78. Aguilar C, Lenoir C, Lambert N, et al. Characterization of Crohn disease in X-linked inhibitor of apoptosis-deficient male patients and female symptomatic carriers. J Allergy Clin Immunol 2014; 134:1131.
  79. Alkhairy OK, Abolhassani H, Rezaei N, et al. Spectrum of Phenotypes Associated with Mutations in LRBA. J Clin Immunol 2016; 36:33.
  80. Segal AW, Loewi G. Neutrophil dysfunction in Crohn's disease. Lancet 1976; 2:219.
  81. Smith AM, Rahman FZ, Hayee B, et al. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease. J Exp Med 2009; 206:1883.
  82. Schäppi MG, Smith VV, Goldblatt D, et al. Colitis in chronic granulomatous disease. Arch Dis Child 2001; 84:147.
  83. Marks DJ, Miyagi K, Rahman FZ, et al. Inflammatory bowel disease in CGD reproduces the clinicopathological features of Crohn's disease. Am J Gastroenterol 2009; 104:117.
  84. Malamut G, Verkarre V, Suarez F, et al. The enteropathy associated with common variable immunodeficiency: the delineated frontiers with celiac disease. Am J Gastroenterol 2010; 105:2262.
  85. Venhoff N, Emmerich F, Neagu M, et al. The role of HLA DQ2 and DQ8 in dissecting celiac-like disease in common variable immunodeficiency. J Clin Immunol 2013; 33:909.
  86. Herbst EW, Armbruster M, Rump JA, et al. Intestinal B cell defects in common variable immunodeficiency. Clin Exp Immunol 1994; 95:215.
  87. Aghamohammadi A, Mohammadinejad P, Abolhassani H, et al. Primary immunodeficiency disorders in Iran: update and new insights from the third report of the national registry. J Clin Immunol 2014; 34:478.
  88. Bonilla FA. Combined B- and T-cell deficiencies. In: Manual of clinical laboratory immunology, 6th ed, Detrick, B, Hamilton, RG, Rose, NR (Eds), ASM Press, Washington, DC 2002. p.819.
  89. Ahmed W, Yusuf R, Hasan I, et al. Fecal indicators and bacterial pathogens in bottled water from Dhaka, Bangladesh. Braz J Microbiol 2013; 44:97.
  90. Igbeneghu OA, Lamikanra A. The bacteriological quality of different brands of bottled water available to consumers in Ile-Ife, south-western Nigeria. BMC Res Notes 2014; 7:859.
  91. Bharath J, Mosodeen M, Motilal S, et al. Microbial quality of domestic and imported brands of bottled water in Trinidad. Int J Food Microbiol 2003; 81:53.
  92. Salcedo J, Keates S, Pothoulakis C, et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 1997; 41:366.
  93. McEldowney SJ, Moss. An uncommon presentation of chronic diarrhea and common variable immunodeficiency improved with IVIG therapy. J Allergy Clin Immunol 2006; 117:S174.
  94. Leung DY, Kelly CP, Boguniewicz M, et al. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991; 118:633.
  95. Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin North Am 2008; 28:413.
  96. Leekha S, Terrell CL, Edson RS. General principles of antimicrobial therapy. Mayo Clin Proc 2011; 86:156.
  97. Cunningham-Rundles C. How I treat common variable immune deficiency. Blood 2010; 116:7.
  98. Chua I, Standish R, Lear S, et al. Anti-tumour necrosis factor-alpha therapy for severe enteropathy in patients with common variable immunodeficiency (CVID). Clin Exp Immunol 2007; 150:306.
  99. Alvarez-Downing MM, Kamal N, Inchauste SM, et al. The role of surgery in the management of patients with refractory chronic granulomatous disease colitis. Dis Colon Rectum 2013; 56:609.
  100. Postgate A, Despott E, Talbot I, et al. An unusual cause of diarrhea: diffuse intestinal nodular lymphoid hyperplasia in association with selective immunoglobulin A deficiency (with video). Gastrointest Endosc 2009; 70:168.
  101. Lai KK, Lamps LW. Enterocolitis in immunocompromised patients. Semin Diagn Pathol 2014; 31:176.
  102. Aslam A, Misbah SA, Talbot K, Chapel H. Vitamin E deficiency induced neurological disease in common variable immunodeficiency: two cases and a review of the literature of vitamin E deficiency. Clin Immunol 2004; 112:24.
Topic Outline